News

Soliris (eculizumab) is currently approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It is not approved in any country

Critical Outcome Technologies president and CEO Dr Wayne Danter said that receiving the Orphan Drug Designation for COTI-2 speaks to the need for new treatment options for patients

OCTAVE is a phase I/II clinical trial to assess the safety and efficacy of its oncolytic vaccine enadenotucirev (previously known as ColoAd1) in platinum-resistant ovarian cancer patients at

These settlements dismiss a pending appeal with the US Court of Appeals for the Federal Circuit of a trial court decision that found the ‘570 patent to be

The Class 1 resubmission follows a complete response letter issued by the FDA that referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured.

Sucampo CEO Peter Greenleaf said that with more than eight million prescriptions dispensed globally over the past eight years, Amitiza has demonstrated to be an effective treatment option

Designed to deliver brief, controlled pulses of nitric oxide, a selective, short-acting pulmonary vasodilator that are inhaled by the patient, the portable device INOpulse enables the treatment of

Manufactured in accordance with the current GMP standards, the therapeutic vaccine is based on a blend of inactivated lactobacilli strains. The primary endpoint of the double-blind and placebo-controlled

The bivalent rLP2086 vaccine is indicated for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25-year-olds. Pfizer vaccine research and development